Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Amortization of Deferred Charges (2016 - 2025)

Dare Bioscience (DARE) has disclosed Amortization of Deferred Charges for 7 consecutive years, with $124251.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Amortization of Deferred Charges changed N/A year-over-year to $124251.0, compared with a TTM value of $135873.0 through Sep 2025, up 150.08%, and an annual FY2017 reading of $316805.0, down 24.57% over the prior year.
  • Amortization of Deferred Charges was $124251.0 for Q3 2025 at Dare Bioscience, up from -$5910.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $124251.0 in Q3 2025 and bottomed at -$5910.0 in Q2 2025.